

Q1 2026 highlights

GSK delivers strong Q1 performance and start to 2026

Total sales

£7.6bn +5%

Specialty Medicines

£3.2bn +14%

Respiratory, Immunology
and Inflammation +16%

Oncology +28%
HIV +10%

Vaccines

£2.1bn +4%

General Medicines

£2.3bn -6%

Core operating profit

£2.7bn +10%

Total EPS

43.2p +15%

Core EPS

46.5p +9%

Dividend

17p

New product approvals in severe asthma, COPD and cancer

Filings achieved for our potential functional cure for hepatitis B

Updated phase III plans for our oncology ADCs

4 further pivotal readouts expected in respiratory disease, HIV and cancer this year

2 pipeline acquisitions completed for assets in food allergies and pulmonary hypertension



Luke Miels,
Chief Executive
Officer, GSK

“GSK has made a strong start to 2026, with good performance from our key growth drivers. Alongside operational delivery, we are focused on execution and accelerating R&D. This is visible in filings we have achieved for bepirovirsen, our potential functional cure for hepatitis B; updated phase III plans for our oncology ADCs; and completed acquisitions for new pipeline assets: ozureprubart for food allergies, and HS235 for pulmonary hypertension.”

Journalists/media see press release on www.gsk.com for full details on Q1 2026.

Please read the cautionary statement regarding forward-looking statements and the definitions and reconciliations for non-IFRS measure on pages 17-18 and pages 42-45 of the press release.

Product group sales may not add to total sales due to rounding.

References to growth are at constant exchange rates (CER) unless stated otherwise.

GSK